167 related articles for article (PubMed ID: 23792589)
1. Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes.
Malhotra A; Shibata Y; Hall IM; Dutta A
Cancer Biol Ther; 2013 Sep; 14(9):840-52. PubMed ID: 23792589
[TBL] [Abstract][Full Text] [Related]
2. Selection of cell lines with enhanced invasive phenotype from xenografts of the human prostate cancer cell line WPE1-NB26.
Rivette AS; Tokar EJ; Williams DE; Mackenzie CD; Ablin RJ; Webber MM
J Exp Ther Oncol; 2005; 5(2):111-23. PubMed ID: 16471037
[TBL] [Abstract][Full Text] [Related]
3. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression.
Webber MM; Quader ST; Kleinman HK; Bello-DeOcampo D; Storto PD; Bice G; DeMendonca-Calaca W; Williams DE
Prostate; 2001 Apr; 47(1):1-13. PubMed ID: 11304724
[TBL] [Abstract][Full Text] [Related]
4. The role of alpha 6 beta 1 integrin and EGF in normal and malignant acinar morphogenesis of human prostatic epithelial cells.
Bello-DeOcampo D; Kleinman HK; Webber MM
Mutat Res; 2001 Sep; 480-481():209-17. PubMed ID: 11506815
[TBL] [Abstract][Full Text] [Related]
5. A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.
Hu DG; Gardner-Stephen D; Severi G; Gregory PA; Treloar J; Giles GG; English DR; Hopper JL; Tilley WD; Mackenzie PI
Mol Pharmacol; 2010 Oct; 78(4):714-22. PubMed ID: 20628005
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.
Pâquet S; Fazli L; Grosse L; Verreault M; Têtu B; Rennie PS; Bélanger A; Barbier O
J Clin Endocrinol Metab; 2012 Mar; 97(3):E428-32. PubMed ID: 22170718
[TBL] [Abstract][Full Text] [Related]
7. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines.
Wijayakumara DD; Hu DG; Meech R; McKinnon RA; Mackenzie PI
J Pharmacol Exp Ther; 2015 Sep; 354(3):417-25. PubMed ID: 26163549
[TBL] [Abstract][Full Text] [Related]
9. Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.
Gauthier-Landry L; Bélanger A; Barbier O
J Steroid Biochem Mol Biol; 2015 Jan; 145():187-92. PubMed ID: 24861263
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.
Margaillan G; Lévesque É; Guillemette C
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):85-93. PubMed ID: 26385605
[TBL] [Abstract][Full Text] [Related]
11. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.
Park JY; Tanner JP; Sellers TA; Huang Y; Stevens CK; Dossett N; Shankar RA; Zachariah B; Heysek R; Pow-Sang J
Urology; 2007 Aug; 70(2):374-9. PubMed ID: 17826523
[TBL] [Abstract][Full Text] [Related]
12. Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.
Kaeding J; Bouchaert E; Bélanger J; Caron P; Chouinard S; Verreault M; Larouche O; Pelletier G; Staels B; Bélanger A; Barbier O
Biochem J; 2008 Mar; 410(2):245-53. PubMed ID: 17988216
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model.
Quader ST; Bello-DeOcampo D; Williams DE; Kleinman HK; Webber MM
Mutat Res; 2001 Sep; 496(1-2):153-61. PubMed ID: 11551491
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
Mimeault M; Johansson SL; Henichart JP; Depreux P; Batra SK
Mol Cancer Ther; 2010 Mar; 9(3):617-30. PubMed ID: 20179163
[TBL] [Abstract][Full Text] [Related]
15. Extracellular redox state regulates features associated with prostate cancer cell invasion.
Chaiswing L; Zhong W; Cullen JJ; Oberley LW; Oberley TD
Cancer Res; 2008 Jul; 68(14):5820-6. PubMed ID: 18632636
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression.
Wu GJ; Wu MW; Wang SW; Liu Z; Qu P; Peng Q; Yang H; Varma VA; Sun QC; Petros JA; Lim SD; Amin MB
Gene; 2001 Nov; 279(1):17-31. PubMed ID: 11722842
[TBL] [Abstract][Full Text] [Related]
17. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications.
Webber MM; Bello D; Quader S
Prostate; 1997 Feb; 30(2):136-42. PubMed ID: 9051152
[TBL] [Abstract][Full Text] [Related]
18. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.
Cai L; Huang W; Chou KC
Protein Pept Lett; 2012 Jan; 19(1):62-9. PubMed ID: 21919858
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel oncogenic events occurring early in prostate carcinogenesis using purified autologous malignant and non-malignant prostate epithelial cells.
Sluka P; Pezaro C; Wardan H; Sengupta S; Davis ID
BJU Int; 2019 May; 123 Suppl 5():27-35. PubMed ID: 30712320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
